German research center Helmholtz Zentrum Munchen announced today that the company had successfully finalized three new spin-offs within the past year to include SurgVision, Trianta Immunotherapies and Dosimetrics.

A new label-free molecular imaging system called the 3D nanoSIMS could provide superior drug research studies at intensely tiny spatial resolutions, announced the National Physical Laboratory in Middlesex, United Kingdom, on Dec. 10.

Average survival for metastatic melanoma patients is less than 5 percent after five years—a disheartening figure, but an investigational agent incorporating benzamide in a melanin-targeted SPECT radiotracer could change the numbers, according to a study published Nov. 16 in the Journal of Nuclear Medicine.

Two novel cardiovascular PET agents are in the wings from FluoroPharma Medical, according to a recent profile in Forbes magazine.

The usual subjects in the Alzheimer’s brain are patterns of beta-amyloid plaque and tau aggregation, but a third perpetrator, clusterin, may be playing a more important role in the development of the disease than previously thought, according to a study published Dec. 30 in JAMA Neurology.

The anesthetic ketamine, used in both humans and animals, may have a new use: treating chronic, drug resistant major depression, according to a study published Jan. 7 in Translational Psychiatry.

The name is fluorodeoxymannose (FDM) and it is giving FDG some competition in the realm of glucose analogue imaging of atherosclerosis, according to a report published Jan. 12 in Nature.

Long past are the days when fluorodeoxyglucose was the primary workhorse for imaging neuroendocrine tumors (NETs). Now there is a veritable cornucopia of agents to choose from, but a family of compounds radiolabeled with gallium-68 have been gaining a lot of headway. These are Ga-68 DOTANOC, DOTATOC and DOTATATE.